SummaryBackgroundThe MTHFR 677C→T polymorphism has been associated with raised homocysteine concentration and increased risk of stroke. A previous overview showed that the effects were greatest in regions with low dietary folate consumption, but differentiation between the effect of folate and small-study bias was difficult. A meta-analysis of randomised trials of homocysteine-lowering interventions showed no reduction in coronary heart disease events or stroke, but the trials were generally set in populations with high folate consumption. We aimed to reduce the effect of small-study bias and investigate whether folate status modifies the association between MTHFR 677C→T and stroke in a genetic analysis and meta-analysis of randomised controlled trials.MethodsWe established a collaboration of genetic studies consisting of 237 datasets including 59 995 individuals with data for homocysteine and 20 885 stroke events. We compared the genetic findings with a meta-analysis of 13 randomised trials of homocysteine-lowering treatments and stroke risk (45 549 individuals, 2314 stroke events, 269 transient ischaemic attacks).FindingsThe effect of the MTHFR 677C→T variant on homocysteine concentration was larger in low folate regions (Asia; difference between individuals with TT versus CC genotype, 3·12 μmol/L, 95% CI 2·23 to 4·01) than in areas with folate fortification (America, Australia, and New Zealand, high; 0·13 μmol/L, −0·85 to 1·11). The odds ratio (OR) for stroke was also higher in Asia (1·68, 95% CI 1·44 to 1·97) than in America, Australia, and New Zealand, high (1·03, 0·84 to 1·25). Most randomised trials took place in regions with high or increasing population folate concentrations. The summary relative risk (RR) of stroke in trials of homocysteine-lowering interventions (0·94, 95% CI 0·85 to 1·04) was similar to that predicted for the same extent of homocysteine reduction in large genetic studies in populations with similar folate status (predicted RR 1·00, 95% CI 0·90 to 1·11). Although the predicted effect of homocysteine reduction from large genetic studies in low folate regions (Asia) was larger (RR 0·78, 95% CI 0·68 to 0·90), no trial has evaluated the effect of lowering of homocysteine on stroke risk exclusively in a low folate region.InterpretationIn regions with increasing levels or established policies of population folate supplementation, evidence from genetic studies and randomised trials is concordant in suggesting an absence of benefit from lowering of homocysteine for prevention of stroke. Further large-scale genetic studies of the association between MTHFR 677C→T and stroke in low folate settings are needed to distinguish effect modification by folate from small-study bias. If future randomised trials of homocysteine-lowering interventions for stroke prevention are undertaken, they should take place in regions with low folate consumption.FundingFull funding sources listed at end of paper (see Acknowledgments).
BACKGROUND
Genetic and environmental factors interact in determining the risk of
venous thromboembolism (VTE). The risk associated with the polymorphic
variants G1691A of factor V (Factor V Leiden,FVL), G20210A
of prothrombin (PT20210A) and C677T of
methylentetrahydrofolate reductase (C677T MTHFR) genes has
been investigated in many studies.
METHODS
We performed a pooled analysis of case-control and cohort studies
investigating in adults the association between each variant and VTE,
published on Pubmed, Embase or Google through January 2010. Authors of
eligible papers, were invited to provide all available individual data for
the pooling. The Odds Ratio (OR) for first VTE associated with each variant,
individually and combined with the others, were calculated with a random
effect model, in heterozygotes and homozygotes (dominant model for
FVL and PT20210A; recessive for
C677T MTHFR).
RESULTS
We analysed 31 databases, including 11,239 cases and 21,521 controls.
No significant association with VTE was found for homozygous C677T
MTHFR (OR: 1.38; 95% confidence intervals [CI]:
0.98–1.93), whereas the risk was increased in carriers of either
heterozygous FVL or PT20210 (OR=4.22; 95%
CI: 3.35–5.32; and OR=2.79;95% CI: 2.25–3.46, respectively),
in double hterozygotes (OR=3.42; 95%CI 1.64-7.13), and in homozygous FVL or
PT20210A (OR=11.45; 95%CI: 6.79-19.29; and OR: 2.79; 95%CI: 2.25 –
3.46, respectively). The stratified analyses showed a stronger effect of
FVL on individuals ≤45 years
(p-value for interaction = 0.036) and of
PT20210A in women using oral contraceptives
(p-value for interaction = 0.045).
CONCLUSIONS
In this large pooled analysis, inclusive of large studies like MEGA,
no effect was found for C677T MTHFR on VTE;
FVL and PT20210A were confirmed to be
moderate risk factors. Notably, double carriers of the two genetic variants
produced an impact on VTE risk significantly increased but weaker than
previously thought.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.